New anticoagulant strategies in ST elevation myocardial infarction: Trials and clinical implications

References

• AntmanEMMorrowDAMcCabeCHEnoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarctionThe New England Journal of Medicine200635414778816537665
   PubMed Web of Science ®Google Scholar
• AntmanEMAnbeDTArmstrongPWACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction – executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction)Circulation200411058863615289388
   PubMed Web of Science ®Google Scholar
• AntmanEMLouwerenburgHWBaarsHFEnoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 TrialCirculation20021051642911940541
   PubMed Web of Science ®Google Scholar
• AntmanEMThe search for replacements for unfractionated heparinCirculation200110323101411342482
   PubMed Web of Science ®Google Scholar
• AntmanEMGiuglianoRPGibsonCMAbciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 InvestigatorsCirculation19999927203210351964
   PubMed Web of Science ®Google Scholar
• AntmanEMTIMI 9B InvestigatorsHirudin in Acute Myocardial Infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B TrialCirculation199694911218790025
   PubMed Web of Science ®Google Scholar
• ArmstrongPWHeparin in acute coronary disease – requiem for a heavyweight?The New England Journal of Medicine199733749249250854
   PubMed Web of Science ®Google Scholar
• Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 InvestigatorsEfficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarctionLancet20013586051311530146
   PubMed Web of Science ®Google Scholar
• BairdSHMenownIBMcBrideSJRandomized comparison of enoxaparin with unfractionated heparin following fibrinolytic therapy for acute myocardial infarctionEuropean Heart Journal2002236273211969277
   PubMed Web of Science ®Google Scholar
• BoersmaEMaasACDeckersJWEarly thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hourLancet199634877158813982
   PubMed Web of Science ®Google Scholar
• BraunwaldEAntmanEMBeasleyJWACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina)Circulation2002106189390012356647
   PubMed Web of Science ®Google Scholar
• ChenZMJiangLXChenYPAddition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trialLancet200536616072116271642
   PubMed Web of Science ®Google Scholar
• CollinsRMacMahonSFlatherMClinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trialsBritish Medical Journal199631365298811758
   PubMed Web of Science ®Google Scholar
• CortiRFusterVBadimonJJPathogenetic concepts of acute coronary syndromesJournal of the American College of Cardiology2003414 Suppl S7S14S12644335
   PubMed Web of Science ®Google Scholar
• CoussementPKBassandJPConvensCA synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE studyEuropean Heart Journal20012217162411511121
   PubMed Web of Science ®Google Scholar
• DaviesMJThe pathophysiology of acute coronary syndromesHeart200083361610677422
   PubMed Web of Science ®Google Scholar
• DeWoodMASporesJNotskeRPrevalence of total coronary occlusion during the early hours of transmural myocardial infarctionThe New England Journal of Medicine19803038979027412821
   PubMed Web of Science ®Google Scholar
• EfirdLEKocklerDRFondaparinux for Thromboembolic Treatment and Prophylaxis of Heparin-Induced ThrombocytopeniaThe Annals of Pharmacotherapy2006401383716788093
   PubMed Web of Science ®Google Scholar
• EikelboomJWQuinlanDJMehtaSRUnfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trialsCirculation200511238556716344381
   PubMed Web of Science ®Google Scholar
• Fibrinolytic Therapy Trialists’ (FTT) Collaborative GroupIndications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patientsLancet1994343311227905143
   PubMed Web of Science ®Google Scholar
• GibsonCMMurphySAMontalescotGPercutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trialJournal of the American College of Cardiology20074922384617560287
   PubMed Web of Science ®Google Scholar
• GiuglianoRPMcCabeCHAntmanEMLower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhageAmerican Heart Journal20011417425011320361
   PubMed Web of Science ®Google Scholar
• GoldbergRJSpencerFAYarzebskiJA 25-year perspective into the changing landscape of patients hospitalized with acute myocardial infarction (the Worcester Heart Attack Study)The American Journal of Cardiology2004941373815566906
   PubMedGoogle Scholar
• GrangerCBBeckerRTracyRPThrombin generation, inhibition and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: results from the GUSTO-I Trial. GUSTO-I Hemostasis Substudy Group. Global Utilization of Streptokinase and TPA for Occluded Coronary ArteriesJournal of the American College of Cardiology1998314975059502626
   PubMedGoogle Scholar
• GrangerCBHirschJCaliffRMActivated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trialCirculation19969387088598077
   PubMed Web of Science ®Google Scholar
• Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto Miocardico (GISSI)Effectiveness of intravenous thrombolytic treatment in acute myocardial infarctionLancet198613974022868337
   PubMed Web of Science ®Google Scholar
• GurmHSLincoffAMLeeDOutcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: lessons from the GUSTO V trialJournal of the American College of Cardiology200443542814975461
   PubMed Web of Science ®Google Scholar
• HirshJFusterVGuide to anticoagulant therapy. Part 1: Heparin. American Heart AssociationCirculation1994891449688124829
   PubMed Web of Science ®Google Scholar
• ISIS-2 (Second International Study of Infarct Survival) Collaborative GroupRandomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2Lancet19882349602899772
   PubMed Web of Science ®Google Scholar
• KeeleyECBouraJAGrinesCLPrimary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trialsLancet2003361132012517460
   PubMed Web of Science ®Google Scholar
• KongDFTopolEJBittlJAClinical outcomes of bivalirudin for ischemic heart diseaseCirculation199910020495310562259
   PubMed Web of Science ®Google Scholar
• MahaffeyKWGrangerCBCollinsROverview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapyThe American Journal of Cardiology19967755168610601
   PubMed Web of Science ®Google Scholar
• MetzBKWhiteHDGrangerCBRandomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb) InvestigatorsJournal of the American College of Cardiology199831149389626825
   PubMed Web of Science ®Google Scholar
• MorenoPRFalkEPalaciosIFMacrophage infiltration in acute coronary syndromes. Implications for plaque ruptureCirculation19949077588044947
   PubMed Web of Science ®Google Scholar
• NeuhausKLMolhoekGPZeymerURecombinant hirudin (lepirudin) for the improvement of thrombolysis with streptokinase in patients with acute myocardial infarction: results of the HIT-4 trialJournal of the American College of Cardiology1999349667310520777
   PubMed Web of Science ®Google Scholar
• RossAMMolhoekPLunderganCRandomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II)Circulation20011046485211489769
   PubMed Web of Science ®Google Scholar
• SabatineMSCannonCPGibsonCMAddition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevationThe New England Journal of Medicine200535211798915758000
   PubMed Web of Science ®Google Scholar
• SciricaBMSabatineMSMorrowDAThe role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction: the ECG CLARITY-TIMI 28 StudyJournal of the American College of Cardiology200648374216814646
   PubMed Web of Science ®Google Scholar
• ShahPKMechanisms of plaque vulnerability and ruptureJournal of the American College of Cardiology2003414 Suppl S15S22S12644336
   PubMed Web of Science ®Google Scholar
• SimoonsMKrzeminska-PakulaMAlonsoAImproved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction. The AMI-SK studyEuropean Heart Journal20022312829012175665
   PubMed Web of Science ®Google Scholar
• StegPGBonnefoyEChabaudSImpact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trialCirculation20031082851614623806
   PubMed Web of Science ®Google Scholar
• StoneGWMcLaurinBTCoxDABivalirudin for patients with acute coronary syndromesThe New England Journal of Medicine200635522031617124018
   PubMed Web of Science ®Google Scholar
• The GUSTO Angiographic InvestigatorsThe effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarctionThe New England Journal of Medicine19933291615228232430
   PubMed Web of Science ®Google Scholar
• WalengaJMJeskeWPBaraLBiochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharideThrombosis Research1997861369172284
   PubMed Web of Science ®Google Scholar
• WallentinLGoldsteinPArmstrongPWEfficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarctionCirculation20031081354212847070
   PubMed Web of Science ®Google Scholar
• WarkentinTELevineMNHirshJHeparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparinThe New England Journal of Medicine1995332133057715641
   PubMed Web of Science ®Google Scholar
• WhiteHHirulog and Early Reperfusion or Occlusion (HERO)-2 Trial InvestigatorsThrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trialLancet200135818556311741625
   PubMed Web of Science ®Google Scholar
• WhiteHDAylwardPEFreyMJRandomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial InvestigatorsCirculation1997962155619337184
   PubMed Web of Science ®Google Scholar
• YusufSMehtaSRChrolaviciusSEffects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trialThe Journal of the American Medical Association2006295151930
   PubMed Web of Science ®Google Scholar
• YusufSMehtaSRXieCEffects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevationThe Journal of the American Medical Association200529342735
   PubMed Web of Science ®Google Scholar